287121-32-8

Basic information

• Product Name: BenzeneMethanol, 5-fluoro-2-nitro-
• Synonyms: BenzeneMethanol, 5-fluoro-2-nitro-;(5-Fluoro-2-nitrophenyl)Methanol
• CAS NO: 287121-32-8
• Molecular Formula: C₇H₆FNO₃
• Molecular Weight: 171.1258432
• Mol File: 287121-32-8.mol

Chemical Properties

• Boiling Point: 286.1°C at 760 mmHg
• Flash Point: 126.8°C
• Appearance: /
• Density: 1.434g/cm³
• Vapor Pressure: 0.00126mmHg at 25°C
• Refractive Index: 1.571
• Storage Temp.: 2-8°C
• PKA: 13.50±0.10(Predicted)
• CAS DataBase Reference: BenzeneMethanol, 5-fluoro-2-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: BenzeneMethanol, 5-fluoro-2-nitro-(287121-32-8)
• EPA Substance Registry System: BenzeneMethanol, 5-fluoro-2-nitro-(287121-32-8)

Safety Data

• Hazardous Substances Data: 287121-32-8(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
Benzenemethanol, 5-fluoro-2-nitro-, is used as a key intermediate in the chemical synthesis industry for the production of various organic compounds. Its unique structure and reactivity make it a valuable building block for the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Benzenemethanol, 5-fluoro-2-nitro-, is utilized as a starting material or intermediate in the synthesis of various drug molecules. Its specific functional groups and substituents can be further modified to create new compounds with desired therapeutic properties.
Used in Research and Development:
Benzenemethanol, 5-fluoro-2-nitro-, is employed in research and development laboratories for studying its chemical properties, reactivity, and potential applications. It serves as a model compound for understanding the behavior of similar aromatic compounds and can be used to develop new synthetic routes and methodologies.
Used in Material Science:
In the field of material science, Benzenemethanol, 5-fluoro-2-nitro-, can be used to develop new materials with specific properties, such as polymers, coatings, or adhesives. Its unique structure and reactivity can contribute to the development of materials with improved performance characteristics.

InChI:InChI=1/C7H6FNO3/c8-6-1-2-7(9(11)12)5(3-6)4-10/h1-3,10H,4H2

Upstream product

• 395-81-3 5-fluoro-2-nitrobenzaldehyde 
• 320-98-9 5-fluoro-2-nitrobenzoic acid 

Downstream Products

• 395-81-3 5-fluoro-2-nitrobenzaldehyde 
• 603306-52-1 5-fluoro-1H-indole-7-carbaldehyde 
• 603306-58-7 2-(dibutoxymethyl)-4-fluoro-1-nitrobenzene 
• 603300-92-1 9-fluoro-3,4-dihydro-1H-[1,4]diazepino[6,7,1-hi]indole-2-carboxylic acid tert-butyl ester 
• 603288-22-8 LY2090314 
• 82420-35-7 2-(bromomethyl)-4-fluoro-1-nitrobenzene 
• 108857-29-0 ethyl (5-fluoro-2-nitrobenzyl)aminoacetate 
• 748805-85-8 (2-amino-5-fluorophenyl)methanol 
• 109115-05-1 5-fluoro-2-nitrobenzyl chloride 
• 951667-32-6 5-[4-nitro-3-hydroxymethyl-phenoxy]-2-(toluene-4-sulfonylamino)-benzoic acid methyl ester 
• 10173-76-9 2-(5-fluoro-2-nitro-phenyl)-1H-benzoimidazole 
• 146829-56-3 2-amino-5-fluoro benzaldehyde 

Relevant articles and documents

Intramolecular Pd-catalyzed reductive amination of enolizable sp3-C-H bonds

A palladium-catalyzed reductive cyclization of nitroarenes has been designed to construct sp3-C-NHAr bonds from sp3-C-H bonds by using an enolizable nucleophile to intercept a nitrosoarene intermediate. Exposure of ortho-substituted nitroarenes to 5 mol ?% of Pd(OAc)2 and 10 mol ?% of phenanthroline under 2 atm of CO constructs partially saturated 5-, 6-, or 7-membered N-heterocycles using α-pyridyl carboxylates, malonates, 1,3-dimethylbarbituric acid, 1,3-diones, or difurans as the nucleophile.

Enantioselective Organocatalytic Intramolecular Aza-Diels–Alder Reaction

A highly efficient catalytic enantioselective intramolecular Povarov reaction was developed with primary anilines as 2-azadiene precursors. A wide variety of angularly fused azacycles were obtained without column chromatography in high to excellent yields and with excellent diastereo- and enantioselectivity (d.r.>99:1 and up to e.r. 99:1). Furthermore, the catalyst loading could be lowered to 1 mol %, and the obtained azacycles could be used as key intermediates for further transformations to generate additional molecular diversity.

Easy Access to Quinolin-2(1 H)-ones via a One-Pot Tandem Oxa-Michael-Aldol Sequence

An efficient strategy for the synthesis of a variety of quinolin-2(1 H)-one derivatives has been developed. The reaction proceeded from cinnamide derivatives via a tandem reaction in the presence of NaOH to afford the corresponding 2- quinolin-2(1 H)-one derivatives in good to excellent yields.

HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM

The present invention concerns a fluorescence resonance energy transfer based high throughput test system to measure the formation of the HIV gp41 six-helix bundle. In a first embodiment the current invention relates to a homogeneous time resolved fluorescence-based test system comprising a first helical polypeptide consisting essentially of the sequence of IQN36 (SEQ ID NO:1); a second helical polypeptide consisting essentially of the sequence of C34 (SEQ ID NO: 2) wherein said IQN36 is labeled with a light emitting fluorophore and said C34 is labeled with an ultra-violet excitable fluorophore.

DIHYDROPYRIDINE DERIVATIVES

The present invention relates to dihydropyridine derivatives having general formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 is (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, phenyl, (1-5C)heteroaryl R2, R3 are independently (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy, (24C)alkenyloxy, (2-4C)alkynyloxy, halogen X is SO2, CH2, C(O) or X is absent R4 is (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, (3-6C)cycloalkyl(1-4C)alkyl, (2-6C)heterocycloalkyl, (2-6C)heterocycloalkyl(14C)alkyl, (6-1 OC)aryl, (6-10C)aryl(1-4C)alkyl, (1-9C)heteroaryl or (1-9C)heteroaryl(14C)alkyl. The compounds are useful for the treatment of fertility disorders.

BENZENESULFONAMIDE INHIBITOR OF CCR2 CHEMOKINE RECEPTOR

Disclosed are compounds of formula (I): or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a combination thereof, as well as compositions of methods of use of the compound, wherein R1, R2, R3, and m ar

DIHYDROPYRIDINE DERIVATIVES

The present invention relates to dihydropyridine derivatives having general formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 is (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, phenyl, (1-5C)heteroaryl R2, R3 are independently (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy, (2-4C)alkenyloxy, (2-4C)alkynyloxy, halogen X is SO2, CH2, C(O) or X is absent R4 is (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, (3-6C)cycloalkyl(1-4C)alkyl, (2-6C)heterocycloalkyl, (2-6C)heterocycloalkyl(1-4C)alkyl, (6-1 OC)aryl, (6-10C)aryl(1-4C)alkyl, (1-9C)heteroaryl or (1-9C)heteroaryl(1-4C)alkyl. The compounds are useful for the treatment of fertility disorders.

Substituted 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-tetrahydro-[1,4] diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3

Glycogen synthase kinase-3 (GSK3) is involved in signaling from the insulin receptor. Inhibitors of GSK3 are expected to effect lowering of plasma glucose similar to insulin, making GSK3 an attractive target for the treatment of type 2 diabetes. Herein we report the discovery of a series of potent and selective GSK3 inhibitors. Compounds 7-12 show oral activity in an in vivo model of type II diabetes, and 9 and 12 have desirable PK properties.

2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS

Compounds having formula (1) are useful in treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss.

PURINE DERIVATIVES AS KINASE INHIBITORS

The present invention provides kinase inhibitors of Formula I.